As Global Biosimilars Week 2026 draws attention to the global value of biosimilar medicines, it also provides an opportunity to consider how significantly the biosimilar landscape has changed. This year marks an important milestone: 20 years since the first biosimilar medicine was approved in the European Union in 2006. What began as a new scientific and regulatory pathway has since developed into an established component of biological medicine, supported by two decades of regulatory assessment, clinical use and accumulated safety experience.
The emergence of biosimilars was made possible by advances in both biotechnology and analytical science. Unlike conventional small-molecule medicines, biological medicines are produced using living systems and are inherently more complex. Developing an alternative biological medicine therefore required a different regulatory approach from the traditional generic medicine’s pathway. Europe became the first region to establish a dedicated framework for biosimilars, developing guidance specifically addressing their quality, non-clinical and clinical evaluation. The first approval in 2006 represented more than the introduction of a new medicine; it demonstrated that a scientifically rigorous pathway could be created for demonstrating that a biological medicine was highly similar to an existing reference product without clinically meaningful differences. Those interested in the history and regulatory development can explore the European Medicines Agency’s overview of biosimilar medicines. and the European Medicines Agency (EMA)
The products themselves have also evolved considerably. Early biosimilars included biological medicines such as Somatropin, Epoetin’s and Filgrastim. Over time, advances in analytical technology, manufacturing capabilities and regulatory experience supported the development of biosimilars for increasingly complex biological medicines, including monoclonal antibodies. This expanded their relevance into therapeutic areas including inflammatory and autoimmune diseases, cancer and diabetes. The United States subsequently established its own biosimilar pathway, with the FDA approving its first biosimilar, Filgrastim-sndz, in 2015. The FDA’s current biosimilar product information resource illustrates just how widely the range of approved products and reference biologics has expanded since then. U.S. Food and Drug Administration
Perhaps one of the most important developments over the past two decades has been the accumulation of real-world experience. Biosimilars entered healthcare at a time when healthcare professionals and patients understandably had questions about what “highly similar” meant in clinical practice. With increasing use came considerably more evidence. In 2022, the EMA and Heads of Medicines Agencies stated that their scientific position on interchangeability was supported by extensive experience with biosimilars in clinical practice, including analysis covering more than one million patient-treatment years of safety data without safety concerns being identified specifically in relation to biosimilarity. The agencies concluded that EU-approved biosimilars are interchangeable with their reference medicines or equivalent biosimilars. The full EMA/HMA position on biosimilar interchangeability provides an important example of how regulatory thinking has evolved alongside accumulated evidence.
The regulatory conversation has evolved as well. Twenty years ago, much of the focus necessarily centred on establishing how biosimilarity could be scientifically demonstrated. Today, regulators have the benefit of extensive analytical, manufacturing, clinical and post-market experience. This does not reduce the standards that biosimilars must meet. Rather, it provides an increasingly mature scientific foundation from which regulators can determine what evidence is most informative when assessing biosimilarity and where unnecessary duplication may potentially be avoided.
The history of biosimilars is therefore not simply a story about increasing numbers of approved products. It is also a story about the development of regulatory science, improvements in analytical technology, greater manufacturing experience and growing familiarity among healthcare professionals and patients.
Twenty years of experience does not mean that the work is complete. Access differs considerably between countries and healthcare systems, and education, regulatory efficiency, sustainable competition and reliable supply remain important considerations. However, the position from which those discussions now take place is very different from that of 2006.
Following Global Biosimilars Week, this anniversary provides a useful perspective. The first 20 years were largely about establishing the science, building regulatory frameworks and accumulating experience. The next chapter is increasingly about how that knowledge can be translated into broader and sustainable patient access to biological medicines.